These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31404795)

  • 1. Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors.
    Zhong Y; Meng Y; Xu X; Zhao L; Li Z; You Q; Bian J
    Bioorg Chem; 2019 Oct; 91():103181. PubMed ID: 31404795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors.
    Wu J; Wang X; Yao Y; Du N; Duan L; Gong P
    Bioorg Chem; 2024 Oct; 151():107556. PubMed ID: 39068717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors.
    Xin M; Sun J; Huang W; Tang F; Liu Z; Jin Q; Wang J
    Future Med Chem; 2020 Oct; 12(19):1691-1707. PubMed ID: 33012191
    [No Abstract]   [Full Text] [Related]  

  • 4. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
    Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
    Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
    Almahli H; Hadchity E; Jaballah MY; Daher R; Ghabbour HA; Kabil MM; Al-Shakliah NS; Eldehna WM
    Bioorg Chem; 2018 Apr; 77():443-456. PubMed ID: 29453076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors.
    Huang M; Ren J; Wang Y; Chen X; Yang J; Tang T; Yang Z; Li X; Ji M; Cai J
    Chem Pharm Bull (Tokyo); 2021; 69(7):620-629. PubMed ID: 34193711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
    Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
    Zhang Z; Chang X; Zhang C; Zeng S; Liang M; Ma Z; Wang Z; Huang W; Shen Z
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1606-1615. PubMed ID: 32779949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors.
    Shen H; Ge Y; Wang J; Li H; Xu Y; Zhu Q
    Bioorg Med Chem Lett; 2021 Sep; 47():128169. PubMed ID: 34091044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1
    Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y
    Molecules; 2019 May; 24(10):. PubMed ID: 31108884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 4,5-dihydrospiro[benzo[c]azepine-1,1'-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation.
    Li S; Li XY; Zhang TJ; Zhu J; Liu KL; Wang DP; Meng FH
    Bioorg Chem; 2021 Jun; 111():104840. PubMed ID: 33780687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of Some Benzimidazole-derived Molecules and their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability.
    Gurkan-Alp AS; Alp M; Karabay AZ; Koc A; Buyukbingol E
    Anticancer Agents Med Chem; 2020; 20(14):1728-1738. PubMed ID: 32357823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
    Yu J; Luo L; Hu T; Cui Y; Sun X; Gou W; Hou W; Li Y; Sun T
    Eur J Med Chem; 2022 Jan; 227():113898. PubMed ID: 34656898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity.
    Zhou J; Ji M; Yao H; Cao R; Zhao H; Wang X; Chen X; Xu B
    Org Biomol Chem; 2018 May; 16(17):3189-3202. PubMed ID: 29648554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.
    Gao CZ; Dong W; Cui ZW; Yuan Q; Hu XM; Wu QM; Han X; Xu Y; Min ZL
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):150-162. PubMed ID: 30427217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
    Xie Z; Zhou Y; Zhao W; Jiao H; Chen Y; Yang Y; Li Z
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4557-61. PubMed ID: 26342868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
    Lin S; Zhang L; Zhang X; Yu Z; Huang X; Xu J; Liu Y; Chen L; Wu L
    Bioorg Med Chem; 2020 May; 28(9):115434. PubMed ID: 32222339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
    Lin C; Liu C; Hu P; Zou Z; Sun G
    Bioorg Chem; 2024 Jul; 148():107455. PubMed ID: 38772289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.
    Yuan Z; Chen S; Chen C; Chen J; Chen C; Dai Q; Gao C; Jiang Y
    Eur J Med Chem; 2017 Sep; 138():1135-1146. PubMed ID: 28763648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of Selective PARP-1 Inhibitors and Antitumor Studies.
    Zhang Y; Li X; Liu F; Bai X; Liu X; Sun H; Gao C; Lin Y; Xing P; Zhu J; Liu R; Wang Z; Dai J; Shi D
    J Med Chem; 2024 Jun; 67(11):8877-8901. PubMed ID: 38776379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.